CLAIMS:

1. A pharmaceutical composition comprising:

   a) a non-steroidal anti-inflammatory drug (NSAID) having a log P value of greater than 2.0;

   b) less than 15% (v/v) of a pharmaceutically-acceptable solvent; wherein the solvent comprises a pharmaceutically-acceptable polyethylene glycol polymer; and

   c) at least 50% (v/v) of a pharmaceutically-acceptable hydrophobic lipid-adjuvant, wherein the pharmaceutically-acceptable hydrophobic lipid-adjuvant is a fatty acid having at least 12 carbons, a glycerolipid, a sphingolipid, a sterol lipid, a prenol lipid, a saccharolipid, or a polyketide,

   wherein the pharmaceutical composition does not comprise a pharmaceutically-acceptable emulsifying agent, and

   wherein the pharmaceutical composition is formulated to be a solid at a temperature of 15°C or lower and have a melting point temperature of about 30°C or higher.

2. The pharmaceutical composition according to Claim 1, wherein the activity that normalizes lipid levels has an anti-hyperlipidemia activity, reduces the level of an inflammation inducing molecule, reduces the level of an inflammation inducing prostaglandin, stimulates a PPAR signaling pathway, induces apoptosis of Macrophage M1 cells, promotes differentiation of Macrophage M2 cells, or both, reduces the levels of Interferon-gamma (IFNγ), Tumor necrosis factor-alpha (TNF-α), Interleukin-12 (IL-12), or a combination thereof released from Th1 cells, increases the levels of IL-10 released from a Th2 cell, or both.

3. The pharmaceutical composition according to Claim 2, wherein the NSAID is a non-selective cyclo-oxygenase (COX) inhibitor, a selective cyclooxygenase 1 (COX 1) inhibitor, a selective cyclooxygenase 2 (COX 2) inhibitor or a combination thereof.

4. The pharmaceutical composition according to any one of Claims 1-3, wherein the NSAID comprises a salicylate derivative NSAID, a p-amino phenol derivative NSAID, a propionic acid derivative NSAID, an acetic acid derivative NSAID, an enolic acid derivative NSAID, a fenamic acid derivative NSAID, a non-selective cyclo-oxygenase inhibitor, a selective cyclooxygenase 1 inhibitor, a selective cyclooxygenase 2 inhibitor or a combination thereof.

5. The pharmaceutical composition according to any one of Claims 1-4, wherein the pharmaceutically-acceptable hydrophobic lipid-adjuvant includes at least 30% of a first glycerolipid consisting of a triglyceride or an acetylated triglyceride and at least 20% of a second glycerolipid consisting of a monoglyceride or an acetylated monoglyceride.

6. The pharmaceutical composition according to any one of Claims 1-8, wherein the pharmaceutically-acceptable solvent is from about 8% (v/v) to about 15% (v/v).

7. The pharmaceutical composition according to any one of Claims 1-6, wherein the pharmaceutically-acceptable solvent is from about 8% (v/v) to about 12% (v/v).

8. The pharmaceutical composition according to any one of Claims 1-7, wherein the glycerolipid comprises a monoglyceride, a diglyceride and/or a triglyceride.

9. The pharmaceutical composition according to Claim 8, wherein the glycerolipid comprises at least 30% of a pharmaceutically-acceptable triglyceride and at least 20% of a pharmaceutically-acceptable monoglyceride.

10. A method of preparing a pharmaceutical composition as defined in Claims 1-9, the method comprising the steps:

    a) contacting a pharmaceutically-acceptable solvent with a therapeutic compound under conditions which allow the therapeutic compound to dissolve in the pharmaceutically-acceptable solvent, thereby forming a solution, and

    b) contacting the solution formed in step (a) with a pharmaceutically-acceptable hydrophobic lipid-adjuvant under conditions which allow the formation of the pharmaceutical composition.

11. Use of a pharmaceutical composition as defined in Claims 1-9 in the manufacture of a medicament for the treatment of a cardiovascular disease.

12. Use of a pharmaceutical composition as defined in Claims 1-9 for the treatment of a cardiovascular disease.

13. The use according to Claim 11 or Claim 12, wherein the cardiovascular disease is associated with a hyperlipidemia, a coronary heart disease, an atherosclerosis, a peripheral vascular disease, a cardiomyopathy, a vasculitis, an inflammatory heart disease, an ischemic heart disease, a congestive heart failure, a hypertensive heart disease, a valvular heart disease, a hypertension, myocardial infarction, a diabetic cardiac conditions, an aneurysm; an embolism, a dissection, a pseudoaneurysm, a vascular malformation, a vascular nevus, a thrombosis, a varicose vein, or a stroke.

CLAIMS:

1. A pharmaceutical composition comprising:

   a) a therapeutic compound having an activity that normalizes lipid levels, wherein the therapeutic compound has a log P value of greater than 2.0;

   b) a pharmaceutically-acceptable solvent; and

   c) a pharmaceutically-acceptable adjuvant, wherein the adjuvant is at least 80% (v/v) of the pharmaceutical composition.

2. The pharmaceutical composition according to Claim 1, wherein the activity that normalizes lipid levels has an anti-hyperlipidemia activity, reduces the level of an inflammation inducing molecule, reduces the level of an inflammation inducing prostaglandin, stimulates a PPAR signaling pathway, induces apoptosis of Macrophage M1 cells, promotes differentiation of Macrophage M2 cells, or both, reduces the levels of Interferon-gamma (IFNγ), Tumor necrosis factor-alpha (TNF-α), Interleukin-12 (IL-12), or a combination thereof released from Th1 cells, increases the levels of IL-10 released from a Th2 cell, or both.

3. The pharmaceutical composition according to Claim 2, wherein the anti-hyperlipidemia activity reduces the levels of VLDL, IDL, LDL, or a combination thereof by at least 10% and/or increases the level of HDL by, e.g., at least 2%

4. The pharmaceutical composition according to any one of Claims 1-3, wherein the therapeutic compound comprises a non-steroidal anti-inflammatory drug (NSAID), a PPARγ agonist, a nuclear receptor binding agent, an anti-hyperlipidemic agent, and/or an ester thereof.

5. The pharmaceutical composition according to Claim 4, wherein the NSAID comprises a salicylate derivative NSAID, a p-amino phenol derivative NSAID, a propionic acid derivative NSAID, an acetic acid derivative NSAID, an enolic acid derivative NSAID, a fenamic acid derivative NSAID, a non-selective cyclo-oxygenase inhibitor, a selective cyclooxygenase 1 inhibitor, a selective cyclooxygenase 2 inhibitor or a combination thereof.

6. The pharmaceutical composition according to Claim 4, wherein the PPARγ agonist comprises Monascin, Irbesartan, Telmisartan, mycophenolic acid, Resveratrol, Delta(9)-tetrahydrocannabinol, a cannabidiol, Curcumin, Cilostazol, Benzbromarone, 6-shogaol, glycyrrhetinic acid, a thiazolidinedione, a NSAID, a fibrate, or a combination thereof.

7. The pharmaceutical composition according to Claim 4, wherein the nuclear receptor binding agent comprises a Retinoic Acid Receptor (RAR) binding agent, a Retinoid X Receptor (RXR) binding agent, a Liver X Receptor (LXR) binding agent, a Vitamin D binding agent, or a combination thereof.

8. The pharmaceutical composition according to Claim 4, wherein the anti-hyperlipidemic agent comprises a fibrate, a statin, a tocotrienol, a niacin, a bile acid sequestrants, a cholesterol absorption inhibitor, a pancreatic lipase inhibitor, a sympathomimetic amine, or a combination thereof.

9. The pharmaceutical composition according to any one of Claims 1-8, wherein the pharmaceutically-acceptable solvent is less than about 20% (v/v).

10. The pharmaceutical composition according to any one of Claims 1-9, wherein the pharmaceutically-acceptable solvent comprises a pharmaceutically-acceptable polar aprotic solvent, a pharmaceutically-acceptable polar protic solvent, a pharmaceutically-acceptable non-polar solvent, or a combination thereof.

11. The pharmaceutical composition according to any one of Claims 1-9, wherein the pharmaceutically-acceptable solvent comprises a pharmaceutically-acceptable alcohol or a pharmaceutically-acceptable ester of pharmaceutically-acceptable alcohol and an acid.

12. The pharmaceutical composition according to any one of Claims 1-11, wherein the pharmaceutically-acceptable adjuvant comprises a pharmaceutically-acceptable lipid.

13. The pharmaceutical composition according to Claim 12, wherein the pharmaceutically-acceptable lipid comprises a saturated fatty acid, an unsaturated fatty acid, or a combination thereof or a pharmaceutically-acceptable oil.

14. The pharmaceutical composition according to any one of Claims 1-13, wherein the pharmaceutical composition further comprises a pharmaceutically-acceptable stabilizing agent, wherein the pharmaceutically-acceptable stabilizing agent is not an emulsifying agent.

15. A method of preparing a pharmaceutical composition as defined in Claims 1-13, the method comprising the steps:

    a) contacting a pharmaceutically-acceptable solvent with a therapeutic compound under conditions which allow the therapeutic compound to dissolve in the pharmaceutically-acceptable solvent, thereby forming a solution, and
    b) contacting the solution formed in step (a) with a pharmaceutically-acceptable adjuvant under conditions which allow the formation of the pharmaceutical composition.

16. The method according to Claim 15, wherein step (a) further comprising contacting a pharmaceutically-acceptable stabilizing agent with the pharmaceutically-acceptable solvent and the therapeutic compound, wherein the pharmaceutically-acceptable stabilizing agent is not an emulsifying agent.

17. The method according to Claim 15 or Claim 16, wherein the method further comprises removing the pharmaceutically-acceptable solvent from the pharmaceutical composition.